Skip to main content
. 2022 Jan 17;12(2):511–527. doi: 10.1007/s13555-021-00675-w

Fig. 3.

Fig. 3

Proportion of patients achieving almost clear to clear skin (baseline treatment cohort). Percentages are based on the number of patients in the FAS3, FAS6 and FAS12 with data available (m) at each visit of interest in the respective baseline treatment cohort. *Secukinumab versus conventional systemics, other biologics versus conventional systemics. FAS3/6/12, full analysis set at month 3, 6 or 12